TRIM44 and hepatocellular carcinoma: Notably, TRIM44 is involved in the occurrence and development of various malignant tumors [7, 13–18], and TRIM44 is overexpressed in various tumours, including prostate cancer [7], gastric cancer [14], hepatocellular carcinoma (HCC) [19], intrahepatic cholangiocarcinoma [15], testicular germ cell tumour [16], lung cancer [17], and oesophageal cancer [18], and is also involved in the metastasis and invasion of malignant tumors [17–20], suggesting that TRIM44 may be a clinically relevant prognostic biomarker and a novel therapeutic target.